Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Synlogic Inc (SYBX)

Synlogic Inc (SYBX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 166,546
  • Shares Outstanding, K 52,373
  • Annual Sales, $ 550 K
  • Annual Income, $ -59,170 K
  • 60-Month Beta 1.87
  • Price/Sales 335.38
  • Price/Cash Flow N/A
  • Price/Book 1.26
Trade SYBX with:

Options Overview Details

View History
  • Implied Volatility 98.13%
  • Historical Volatility 83.17%
  • IV Percentile 28%
  • IV Rank 25.73%
  • IV High 260.61% on 11/04/20
  • IV Low 41.84% on 09/15/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 35
  • Volume Avg (30-Day) 247
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 126
  • Open Int (30-Day) 240

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.30
  • Number of Estimates 5
  • High Estimate -0.29
  • Low Estimate -0.32
  • Prior Year -0.36
  • Growth Rate Est. (year over year) +16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.54 +24.80%
on 08/27/21
4.04 -21.53%
on 09/20/21
+0.54 (+20.53%)
since 08/24/21
3-Month
2.41 +31.54%
on 08/20/21
4.38 -27.63%
on 06/25/21
-1.18 (-27.13%)
since 06/24/21
52-Week
1.78 +78.09%
on 11/02/20
5.11 -37.96%
on 02/10/21
+1.17 (+58.50%)
since 09/24/20

Most Recent Stories

More News
Microbiome Therapeutics Market Research By Production, Revenue, Sales Value, Industry Trends, Impact Factors And SWOT Analysis 2029

Research Nester released a report titled which delivers a detailed overview of the global microbiome therapeutics market in terms of market segmentation by application and by region.

DD : 68.25 (-0.94%)
DDDD.LN : 66.500 (-1.34%)
PHGE : 3.17 (+2.59%)
SYBX : 3.17 (-0.31%)
MCRB : 6.94 (-2.12%)
Synlogic Announces Pricing of Public Offering of Common Stock

Sept. 22, 2021 /PRNewswire/ --  (Nasdaq: SYBX) a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the pricing of its underwritten public...

SYBX : 3.17 (-0.31%)
Synlogic Announces Proposed Public Offering of Common Stock

/PRNewswire/ -- Synlogic (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has commenced an underwritten public offering...

SYBX : 3.17 (-0.31%)
Synlogic Announces Positive Phase 2 Data Demonstrating Reduction in Plasma Phenylalanine Levels in Patients with Phenylketonuria

/PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced positive data from clinical studies evaluating...

SYBX : 3.17 (-0.31%)
Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting

/PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it will present data on SYNB8802, an...

SYBX : 3.17 (-0.31%)
Synlogic Presents at Global PKU Patient Meeting

/PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented on the development of investigational Synthetic...

SYBX : 3.17 (-0.31%)
Phenylketonuria Drugs Market- Demand, Trends, Share,Global Demand Analysis and Opportunity Outlook 2029

Research Nester published a report titled  which delivers detailed overview of the global phenylketonuria drugs market in terms of market segmentation by drug type, route of administration, end users,...

RARE : 95.11 (-2.45%)
PTCT : 39.29 (-0.48%)
BMRN : 78.60 (-0.88%)
FIXX : 8.64 (-0.80%)
RUBY : 18.60 (-3.63%)
SYBX : 3.17 (-0.31%)
BioMarin (BMRN) Phenylketonuria Gene Therapy on Clinical Hold

BioMarin's (BMRN) phase I/II study on gene therapy candidate, BMN 307, has been placed under a clinical hold by the FDA possibly on malignancy concerns.

RDY : 64.87 (-0.28%)
ENDP : 3.25 (-3.85%)
BMRN : 78.60 (-0.88%)
SYBX : 3.17 (-0.31%)
Global Phenylketonuria Drugs Market- Analysis By Recent Trends, Development And Growth Forecast To 2027

Research Nester published a report titled  which delivers detailed overview of the global phenylketonuria drugs market in terms of market segmentation by drug type, route of administration, end users,...

RARE : 95.11 (-2.45%)
PTCT : 39.29 (-0.48%)
BMRN : 78.60 (-0.88%)
FIXX : 8.64 (-0.80%)
RUBY : 18.60 (-3.63%)
SYBX : 3.17 (-0.31%)
Synlogic, Inc. (SYBX) Reports Q2 Loss, Tops Revenue Estimates

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 3.45% and 23.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

SYBX : 3.17 (-0.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The company's pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases such as Urea Cycle Disorder and Phenylketonuria....

See More

Key Turning Points

3rd Resistance Point 3.43
2nd Resistance Point 3.37
1st Resistance Point 3.27
Last Price 3.17
1st Support Level 3.11
2nd Support Level 3.05
3rd Support Level 2.95

See More

52-Week High 5.11
Fibonacci 61.8% 3.84
Fibonacci 50% 3.45
Last Price 3.17
Fibonacci 38.2% 3.05
52-Week Low 1.78

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar